Lions Bay Mining News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.08.21	Klinische Studie bestätigt, dass der CoviDTH-Diagnoseansatz zum Screening auf T-Zell-vermittelte Immunantwort auf SARS-CoV-2 sicher und wirksam beim Menschen ist (PR Newswire)
03.08.21	Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans (PR Newswire)
03.08.21	Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans (PR Newswire)
03.08.21	Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans (PR Newswire)
03.08.21	Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans (PR Newswire)
29.07.21	BioVaxys Closes Final Tranche Of Non-Brokered Private Placement (PR Newswire)
29.07.21	BioVaxys Closes Final Tranche Of Non-Brokered Private Placement (PR Newswire)
23.07.21	FDA stellt BioVaxys notwendige Leitlinien bereit, um mit der IND-Vorbereitung für klinische Phase-I/II-Studien mit CoviDTH zu beginnen (PR Newswire)
22.07.21	FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH (PR Newswire)
22.07.21	FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH (PR Newswire)
22.07.21	FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH (PR Newswire)
22.07.21	FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH (PR Newswire)
30.06.21	BioVaxys kündigt eine nicht von einem Broker vermittelte Privatplatzierung an (PR Newswire)
29.06.21	BioVaxys Announces Non-Brokered Private Placement (PR Newswire)
29.06.21	BioVaxys Announces Non-Brokered Private Placement (PR Newswire)
29.06.21	BioVaxys Announces Non-Brokered Private Placement (PR Newswire)
29.06.21	BioVaxys Announces Non-Brokered Private Placement (PR Newswire)
15.06.21	BioVaxys erhält positiven Bescheid der FDA bezüglich Pre-IND Review für die klinische Entwicklung von CoviDTH (PR Newswire)
14.06.21	BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development (PR Newswire)
02.06.21	BioVaxys und Bioproduktionspartner Bio Elpida beginnen mit dem Bau einer GMP-Anlage zur Produktion von klinischem Material für die geplante Impfstoffstudie gegen Eierstockkrebs (PR Newswire)
01.06.21	BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study (PR Newswire)
01.06.21	BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study (PR Newswire)
01.06.21	BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study (PR Newswire)
01.06.21	BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study (PR Newswire)
24.05.21	Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing (PR Newswire)
24.05.21	Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing (PR Newswire)
24.05.21	Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing (PR Newswire)
24.05.21	Biovaxys stärkt interne Expertise mit der Ernennung eines wissenschaftlichen Beraters für das klinische Programm zum Impfstoff gegen Eierstockkrebs und die Vermarktung von Papilocare (PR Newswire)
24.05.21	Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing (PR Newswire)
21.05.21	BioVaxys gibt Ernennung eines Policy Advisor bekannt (PR Newswire)
20.05.21	BioVaxys Announces Appointment of Policy Advisor (PR Newswire)
20.05.21	BioVaxys Announces Appointment of Policy Advisor (PR Newswire)
20.05.21	BioVaxys Announces Appointment of Policy Advisor (PR Newswire)
20.05.21	BioVaxys Announces Appointment of Policy Advisor (PR Newswire)
20.05.21	BioVaxys kündigt Uplisting an den OCTQB Venture Market an (PR Newswire)
19.05.21	BioVaxys Announces Uplisting To The OCTQB Venture Market (PR Newswire)
19.05.21	BioVaxys Announces Uplisting To The OCTQB Venture Market (PR Newswire)
19.05.21	BioVaxys Announces Uplisting To The OCTQB Venture Market (PR Newswire)
04.05.21	Impfstoffe gegen Eierstockkrebs: BioVaxys und BioElpida unterzeichnen endgültige Exklusivvereinbarung zum Beginn der Bioproduktion (PR Newswire)
03.05.21	BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction (PR Newswire)
03.05.21	BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction (PR Newswire)
03.05.21	BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction (PR Newswire)
03.05.21	BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction (PR Newswire)
02.05.21	BioVaxys erweitert Patent-Portfolio und reicht gewerbliche Markenanmeldung für CoviDTH®-Test ein (PR Newswire)
29.04.21	BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH(R) Diagnostic (PR Newswire)
29.04.21	BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic (PR Newswire)
29.04.21	BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic (PR Newswire)
29.04.21	BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic (PR Newswire)
21.04.21	BioVaxys Assigned "BVAXF" By Finra As New US OTC Trading Symbol (PR Newswire)
21.04.21	BioVaxys Assigned "BVAXF" By Finra As New US OTC Trading Symbol (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’833.00	0.87 %	K V
Nestle	90.24	0.78 %	K V
Roche Hldg G	296.70	0.78 %	K V
Sonova Hldg	262.80	0.42 %	K V
Kuehne+Nagel Int	206.70	0.39 %	K V
Part Grp Hldg	1’291.50	-1.45 %	K V
Logitech Intl	77.34	-1.65 %	K V
Geberit	558.20	-1.86 %	K V
ABB	46.96	-2.69 %	K V
Swisscom	513.00	-3.93 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lions Bay Mining Aktie VALOR 57530891 / ISIN CA09076M1014

Nachrichten zu Lions Bay Mining Corp Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten